On June 7, 2021, the FDA made a controversial and unexpected decision to greenlight a novel therapy for Alzheimer’s disease, the first approved for this condition since 2003. ADUHELM (aducanumab), manufactured by Biogen, marks a new class of cognitive therapy – a monoclonal antibody directed at amyloid beta aggregates and soluble oligomers, the pathologic hallmark of Alzheimer’s disease.